On December 24, 2020, RealClearHealth published an op-ed by Aimed Alliance counsel Stacey Worthy. The op-ed discusses CVS Caremark’s proposed formulary changes, which includes eliminating coverage for certain selective serotonin reuptake inhibitors (SSRIs) used to treat depression at the beginning of the new year. This change would force patients to switch their treatments and leave them vulnerable to gaps in their treatment, potential side effects arising from the switch, and negative health results. The op-ed calls for CVS Caremark to allow patients to remain on their current SSRIs in 2021 and prevent non-medical switching, which could prove detrimental to currently stable patients when compounded by seasonal depression trends and the effects of the COVID-19 pandemic. Read the op-ed here.